Prostatitis Therapeutics Pipeline to Witness Remarkable Growth due to Increased Number of Pipeline Candidates by Drug Developers | Top key players are Aquinox Pharmaceuticals, Inc., AbbVie, Pfizer, The Janssen Pharmaceutical Companies of Johnson & Johnson
Download the sample report at: https://www.pharmaproff.com/request-sample/1239
The chronic pelvic pain syndrome leads to pain in penis, lower back, scrotum, central lower abdomen, and between scrotum and anus, acute bacterial prostatitis and chronic bacterial prostatitis tend to change urinary frequency, fever, chills, burning sensation during urination, urinary blockage, nausea, and vomiting, whereas patients with asymptomatic prostatitis do not have symptoms of prostatitis.
The occurrence of prostatitis can be diagnosed by a physical examination, blood test digital rectal exam (DRE), prostate-specific antigen (PSA) blood test, and cystoscopy and urodynamic tests. Some of the commonly used treatment options include medications (antibiotics, alpha-blockers, and anti-inflammatory agents), lifestyle changes, and acupuncture.
Get the detailed analysis at: https://www.pharmaproff.com/report/prostatitis-therapeutics-pipeline
In addition, Rapaflo (Kissei Pharmaceutical Co. Ltd.), Proscar (Merck & Co. Inc.), Avodart (GlaxoSmithKline plc), and Pamelor (Mallinckrodt LLC) are some of the drugs approved by the U.S. Food and Drug Administration (USFDA) for the treatment of prostatitis.
According to the research findings, majority of the pipeline drug candidates are being developed for oral administration. It has been observed that the oral route of medications is convenient, available in delayed or rapid release formulation, less risk of systemic infections, and inexpensive in nature, and also provides improved patient’s compliance.
Make enquiry before purchase at: https://www.pharmaproff.com/enquiry/1239
Companies that are involved in developing therapeutics for prostatitis have shown positive clinical results in the various phases of drug development. For instance, in September 2018, Santen Pharmaceutical Co. Ltd. announced positive data from the phase III trial of Opsiria for the treatment of patients with prostatitis. The results of the study concluded that the treatment with Opsiria had a favorable safety and tolerability profile. The study also recorded efficacy of Opsiria in lowering down the inflammation in eyes.
Global Market of Prostatitis Therapeutics is Expected to Increase Statistically in the next 10 years
Humira (AbbVie Inc.), Geocillin (Pfizer Inc.), Floxin (Ortho-McNeil-Janssen Pharmaceuticals Inc.), and Levaquin (Janssen Pharmaceuticals Inc.) are the approved drugs for the treatment of prostatitis and with the emergence of late- and mid-stage pipeline products in the market, the overall prostatitis therapeutics market is expected to grow significantly in the upcoming years.
Aquinox Pharmaceuticals Inc., AbbVie Inc., Pfizer Inc., Kissei Pharmaceutical Co. Ltd., Janssen Pharmaceuticals Inc., Merck & Co. Inc., Santen Pharmaceutical Co. Ltd., Aldeyra Therapeutics Inc., Ortho-McNeil-Janssen Pharmaceuticals Inc., GlaxoSmithKline plc, Mallinckrodt LLC, and Novartis AG are some of the key players involved in the development of therapeutic drugs indicated for the treatment of prostatitis.
The report comprises detailed pipeline analysis of therapeutics being developed for the treatment of prostatitis. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the prostatitis therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in the report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to prostatitis.
Toll-free: +1-888-778-7886 (USA/Canada)
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Prostatitis Therapeutics Pipeline to Witness Remarkable Growth due to Increased Number of Pipeline Candidates by Drug Developers | Top key players are Aquinox Pharmaceuticals, Inc., AbbVie, Pfizer, The Janssen Pharmaceutical Companies of Johnson & Johnson here
News-ID: 1777616 • Views: 699
More Releases for Pharma
Global Deferasirox Market 2018 - Novartis, Cipla, Sun Pharma, Natco Pharma
Apex Market Reports, recently published a detailed market research study focused on the “Deferasirox Market” across the global, regional and country level. The report provides 360° analysis of “Deferasirox Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Deferasirox on the basis of
Big Pharma Outlook 2026
Boston, MA ReportsWorldwide has announced the addition of a new report title Big Pharma Outlook 2026 to its growing collection of premium market research reports. Pharmavitae Analytics casts its eye out to 2026 with challenging trends in healthcare management set to crystallize, Big Pharma will add $29.5bn in revenues out to 2026, generating $351bn in prescription pharmaceuticals at a low single-digit compound annual growth rate (CAGR) of 0.9%. Using in-house sales forecasts,
Clomifene Citrate Market 2017 - Sanofi, Palam Pharma, Bioxera, Zafax Pharma
Apex Research, recently published a detailed market research study focused on the "Clomifene Citrate Market" across the global, regional and country level. The report provides 360° analysis of "Clomifene Citrate Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Clomifene Citrate industry, and estimates the future trend of Clomifene Citrate market on
12th World Pharma Congress
Conference Series proudly announces 12th World Pharma Congress for 2017, during October 16-18, at Budapest, Hungary. Pharmaceutical innovation is an orderly, predictable process. Intensive research coverage is resulting in an abundant knowledge of the mechanisms driving drug discovery and development. Pharmaceutical Formulation Market size was USD $147billion in 2015 and is anticipated to reach around USD 175.1 billion by 2018. In USA, the total number of new drugs approved between
12th World Pharma Congress
Conference Series has taken an initiation to conduct International Pharma Congress worldwide. From several years Conference Series has been conducting Pharma Congress conferences in major continents like Europe, America and Asia Pacific. Previous conferences were held in city like USA, with success. Conference Series proudly announces 12th World Pharma Congress for 2017, during October 16-18, at Budapest, Hungary. Pharmaceutical innovation is an orderly, predictable process. Intensive research coverage is resulting
4th African Pharma Congress
In the light of this theme, the conference series aims to provide a forum for international researchers from various areas of pharmaceutical sciences like chemical processing, industrial practice, analytical methods and pharmacological actions by providing a platform for critical analysis of new agenda, and to share latest cutting-edge research findings and results about all aspects of Pharmacy We are honoured to invite pharmacists, researchers, professors, scientific communities, delegates, students, business